Impossible Asks: Can the Transparency and Consent Framework Ever Authorise Real-Time Bidding After the Belgian DPA Decision?
Technology and Regulation · 2022
DOI: 10.71265/0ccteg67 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology and Regulation, 2022. Verfasst von Michael Veale und 2 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
On 2 February 2022, the Belgian Data Protection Authority handed down a decision concerning IAB Europe and its Transparency and Consent Framework (TCF), a system designed to facilitate compliance of real-time bidding (RTB), a widespread online advertising approach, with the GDPR. Here, we summarise and analyse this large, complex case. We argue that by characterising IAB Europe as a joint controller with RTB actors, this important decision gives DPAs an agreed-upon blueprint to deal with a structurally difficult enforcement challenge. Furthermore, under the DPA’s simple-looking remedial orders are deep technical and organisational tensions. We analyse these “impossible asks”, concluding that absent a fundamental change to RTB, IAB Europe will be unable to adapt the TCF to bring RTB into compliance with the decision.
Zitieren
APA
Veale, M., Nouwens, M., & Santos, C. (2022). Impossible Asks: Can the Transparency and Consent Framework Ever Authorise Real-Time Bidding After the Belgian DPA Decision?. Technology and Regulation. https://doi.org/10.71265/0ccteg67
Vancouver
Veale M, Nouwens M, Santos C. Impossible Asks: Can the Transparency and Consent Framework Ever Authorise Real-Time Bidding After the Belgian DPA Decision?. Technology and Regulation. 2022. doi:10.71265/0ccteg67
BibTeX
@article{Veale2022,
author = {Veale, Michael and Nouwens, Midas and Santos, Cristiana},
title = {Impossible Asks: Can the Transparency and Consent Framework Ever Authorise Real-Time Bidding After the Belgian DPA Decision?},
journal = {Technology and Regulation},
year = {2022},
doi = {10.71265/0ccteg67}
}
EUVIMED